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Secure determination of the binding of99mTc-radiopharmaceuticals to plasma
(P) and blood cell (BC) constituents can help to understand the biodistribution
of radiophamaceuticals. The reported precipitation studies ofblood with radio-
pharmaceuticals have shown that the results can not be easily compared
between studies. We decided to determine the "gold standard" concentration of
trichloroacetic acid (TCA) to evaluate the binding to blood elements for sever-
al radiopharmaceuticals used in routine nuclear medicine. We have studied
phytic (99mTc-PHY), diethylenetriaminepentaacetic (99mTc-DTPA), gluco-
heptonic (99mTc-GHA) and dimercaptosuccinic (99mTc-DMSA) acids. Blood
was incubated with radiopharmaceuticals, centrifuged and P and BC separated.
Samples of P and BC were also precipitated with TCA concentrations (20.0,
10.0, 5.0, 1.0, 0.5 and 0.1 percent) and soluble (SF) and insoluble fractions (IF)
were isolated. The percent radioactivity (percent rad) in IF-P depends on TCA
concentration. It varied from 36.4 to 65.0 (99mTc-PHY), from 17.9 to 32.0
(99mTc-DTPA), from 11.5 to 38.8 (99mTc-GHA) and from 52.8 to 66.2
(99mTc-DMSA). The results for the binding of99mTc-PHY to IF-P show that
there was no differences in the percent rad when TCA concentrations of 0.1 to
1.0 percent were used. For 99mTc-DTPA, 5.0 percent is the best TCA concen-
tration. For99mTc-GHA, low values ofpercent rad bound to IF-P is found with
TCA concentrations of0.1, 0.5 and 1.0. Interestingly, with 99mTc-DMSA, high
values ofbound radioactivity are not dependent on TCA concentrations (0.1 to
10.0). Radioactivity in IF-BC depends on TCA concentration and it varied for
99mTc-PHY (80.1 to 54.1) and for 99mTc-GHA (85.5 to 61.7). With 99mTc-
DTPA and with 99mTc-DMSA the percent rad in IF-BC seems independent of
TCA concentration. We suggest that the evaluation ofthe binding ofthe various
99mTc-radiopharmaceuticals to blood constituents, using only one TCA con-
centration, should be avoided.
INTRODUCTION
Secure determination of the binding of 99mTc-radiopharmaceuticals to plasma pro-
teins and blood cell constituents can help to understand the uptake of radiopharmaceuti-
cals in targets in human beings. Many factors can affect the biodistribution ofradiophar-
maceuticals. If unknown, such factors may lead to poor organ visualization, requiring
repeat examinations and increasing the radiation dose to the patient [1-3].
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There is considerable evidence that the biodistribution or radiopharmacokinetics of
radiopharmaceuticals may be altered by a variety of drugs. One reason for this observa-
tion is the effect ofthe drug in interfering with the binding ofthe radiopharmaceuticals to
plasma proteins and/or blood cell constituents. Accurate, precise and reproducible deter-
mination ofthe radioactivity bound to blood elements is worthwhile (i) to understand how
a drug is capable ofmodifying the biodistribution ofradiopharmaceuticals and (ii) to eval-
uate the specific characteristics ofthe binding ofeach radiopharmaceutical to their targets
in the blood. There are different methods to quantitate the binding to bloodelements, how-
ever it is known that determination of protein-binding involves many problems and the
results normally are not unequivocal. Precipitation methods are generally reliable, while
the dialysis method, which is widely used, is dependent on the association-dissociation
equilibrium between the 99mTc-radiopharmaceutical and the protein that complexes with
it. By application of dialysis or gel chromatography, only the technetium that is irre-
versibly bound to proteins is observed [4-8]. If the values obtained depend on the short-
term stability of the 99mTc-radiopharmaceutical-protein complex, these methods do not
provide clear data.
Several 99mTc-radiopharmaceuticals are employed in different static and dynamic
procedures in nuclear medicine in various organs and systems. Phytic acid (99mTc-PHY)
(liver and spleen), glucoheptonic acid (99mTc-GHA) and diethylenetriaminepentaacetic
acid (99mTc-DTPA) (kidneys and brain), dimercaptosuccinic acid (99mTc-DMSA) (kid-
neys), iminodiacetic acid analogs (99mTc-IDA) (liver and biliary function), methyl-
enediphosphonic acid (99mTc-MDP) (bone), hexamethylpropyleneamineoxime (99mTc-
HMPAO) (brain and inflammatory processes) and 2-methoxyisobutylisonitrile (99mTc-
MIBI) (heart and oncologic processes), besides others are usually utilized [1, 2].
The elucidation of the binding of radiopharmaceuticals to blood is worthwhile, and
theoretical and practical aspects of this binding with plasma (P) have been studied,
although blood cells (BC) have not been adequately evaluated and the results can not be
easily compared. Thus, we decided to determine the "gold standard" concentration of
trichloroacetic acid(TCA) foreachradiopharmaceutical in order to determine the radioac-
tivity present in precipitation of P and BC. In this study, we compare the results obtained
with 99mTc-radiopharmaceuticals: 99mTc-PHY, 99mTc-GHA, 99mTc-DMSA and
99mTc-DTPA.
MATERIAL AND METHODS
The experiments were carried out with heparinized whole blood withdrawn from
Wistar rats (sex: male, weight: 120 g, age: four months). The employed kits (PHY, GHA,
DMSA and DTPA) were obtained from the Radiopharmacy Department, Instituto
Nacional de Cancer, Rio de Janeiro, Brazil. 99mTc, as sodium pertechnetate was obtained
from a 99Mo/99mTc generator purchased from Instituto de Pesquisas Energeticas e
Nucleares, Comissao Nacional de Energia Nuclear, Brazil and was added to the kits to
prepare 99mTc-PHY, 99mTc-GHA, 99mTc-DMSA and 99mTc-DTPA.
Fresh whole blood (3 ml) was isolated and incubated with recently prepared samples
(1 ml) of the 99mTc-radiopharmaceuticals (99mTc-PHY, 99mTc-GHA, 99mTc-DMSA
and 99mTc-DTPA) (3.7 MBq) for 60 min at room temperature. After these incubations,
the blood preparations were centrifuged and plasma (P) and blood cells (BC) were isolat-
ed.Aliquots (20VI) ofP and BC were precipitated with 1 ml ofsolutions oftrichloroacetic
acid (Reagen, Brazil) in various concentrations (20.0, 10.0, 5.0, 1.0, 0.5, 0.1 percent) and
soluble (SF) and insoluble (IF) fractions from plasma and blood cells were separated. The
several samples (P, BC, IF-P, SF-P, IF-BC and SF-BC) were counted in a well counter
with NaI(Tl) crystal (1272 Clinigamma Gamma Counter, LKB Wallac, Finland).
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The percentage ofradioactivity (percent rad) in P was determined dividing the counts
in P by the sum of the counts in P plus BC, percent rad in BC was determined dividing
the counts in BC by the sum of the counts in P plus BC, percent rad in IF-P was deter-
mined dividing the counts in IF-P by the sum ofthe counts in IF-P plus SF-P and percent
rad in IF-BC was determined dividing the counts in IF-BC by the sum ofthe counts in IF-
BC plus SF-BC. The values were multiplied by 100.
RESULTS
Table 1 shows the distribution on plasma and blood cells ofthe 99mTc-radiopharma-
ceuticals that were incubated with whole blood for 60 min. As expected, the radiophar-
maceuticals that are used for renal evaluations (99mTc-DTPA, 99mTc-GHA and 99mTc-
DMSA) are mainly found in plasma. However, most of the 99mTc-PHY is found in the
blood cell fraction.
Table 2 shows the percent rad in insoluble fractions obtained from plasma samples
precipitated with different trichloroacetic concentrations. These samples of plasma were
obtained from whole blood that had been incubated for 60 min with the radiopharmaceu-
Table 1. Distribution of the radioactivity of different radiopharmaceuticals in plasma and
blood cell fractions.
Radiopharmaceutical Plasma (P) Blood cells (BC)
99mTc-DTPA 88.6 ± 5.8 11.4 ± 5.8
99mTc-GHA 76.5 ± 5.4 23.5 ± 5.4
99mTc-DMSA 83.5 ± 4.8 16.5 ± 4.8
99mTc-PHY 27.5 ± 5.5 72.5 ± 5.5
Fresh whole blood was incubated with samples of the 99mTc-radiopharmaceuticals (99mTc-PHY,
99mTc-GHA, 99mTc-DMSA and 99mTc-DTPA) for 60 min at room temperature. After these incu-
bations, the blood preparations were centrifuged and plasma (P) and blood cells (BC) were isolat-
ed. The several samples (P and BC) were counted in a well counter with NaI(TM) crystal. Percentage
ofradioactivity (percent rad) in P was determined dividing the counts in P by the sum ofthe counts
in P plus BC and percent rad in BC was determined dividing the counts in BC by the sum of the
counts in P plus BC. The values found were multiplied by 100. The values are averages ± standard
deviations of 8 experiments.
ticals. The percent rad in IF-P depends on TCA concentration and it varied from 36.4 to
65.0 (99mTc-PHY), from 17.9 to 32.0 (99mTc-DTPA), from 11.5 to 38.3 (99mTc-GHA)
and from 52.8 to 66.2 (99mTc-DMSA). The results obtained for the fixation of 99mTc-
PHY in the IF-P show that there is no differences in the percent rad when TCA concen-
trations of 0.1 to 1.0 percent were used for precipitation. For 99mTc-DTPA, 5.0 percent
TCA concentration is the best one to precipitate the bound radiopharmaceutical. For
99mTc-GHA, lower values of percent rad bound to insoluble fraction ofplasma is found
for the TCA concentrations of 0.1, 0.5 and 1.0. However, for 99mTc-DMSA the highest
values ofbound radioactivity are not dependent on TCA concentration in the range of0.1
to 10.0 percent.
Table 3 shows the percent rad in insoluble fractions obtained from blood samples pre-
cipitated with different trichloroacetic concentrations. These samples of blood cells were
obtained from whole blood that was incubated for 60 min with the given radiopharmaceu-
tical. The percent rad in IF-BC depends on TCA concentration and it varied for 99mTc-
PHY (80.1 to 54.1) and for 99mTc-GHA (85.5 to 61.7). However, to 99mTc-DMSA and
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Table 2. Distribution of the percent of radioactivity in insoluble fractions obtained with the
precipitation ofsamples ofplasma with different trichloroacetic acid (TCA) concentrations.
TCA conc. (%) Insoluble fraction
99mTc-PHY 99mTc-DTPA 99mTc-GHA 99mTc-DMSA
0.1 64.3± 1.6 17.9±4.1 15.2 ±5.0 63.6±7.6
0.5 62.4 ± 9.4 23.8 ± 11.5 11.5 ±3.0 66.2 ± 2.7
1.0 65.0±6.4 24.9±9.1 19.3±5.1 65.2±9.1
5.0 45.6 ± 9.5 32.0 ± 0.7 38.3 ± 2.5 64.8 ± 4.8
10.0 38.1 ± 9.9 26.9 ± 2.8 36.8 ± 4.6 60.7 ± 4.8
20.0 36.4 ± 4.9 26.0 ± 6.8 35.8 ± 5.7 52.8 ± 4.7
Fresh whole blood was incubated with 99mTc-radiopharmaceuticals (99mTc-PHY, 99mTc-GHA,
99mTc-DMSA and 99mTc-DTPA) for 60 min at room temperature. After these incubations, the
blood preparations were centrifuged and plasma (P) and blood cells (BC) were isolated. Aliquots of
P and BC were precipitated with solutions of trichloroacetic acid at various concentrations (20.0,
10.0, 5.0, 1.0, 0.5, 0.1 percent) and soluble (SF) and insoluble (IF) fractions from plasma were sep-
arated. The samples were counted in a well counter with NaI(Tl) crystal and the percentage of
radioactivity (percent rad) in IF-P was determined dividing the counts in IF-P by the sum of the
counts in IF-P plus SF-P. The values found were multiplied by 100. The values are averages ± stan-
dard deviations of 8 experiments.
99mTc-DTPA, the percent rad in the insoluble fraction seems to be independent of the
TCA concentration.
DISCUSSION
The distribution ofradioactivity ofthe radiopharmaceuticals in plasma and blood cell
compartments has been studied by several authors. The results described here (Table 1)
for 99mTc-PHY, 99mTc-DTPA, 99mTc-GHA and 99mTc-DMSA are in agreement with
Table 3. Distribution of the percent of radioactivity in insoluble fractions obtained with the
precipitation ofsamples ofblood cells with different TCA concentrations.
TCA conc. (%) Insoluble fraction
99mTc-PHY 99mTc-DTPA 99mTc-GHA 99mTc-DMSA
0.1 80.1 ± 1.3 63.5 ± 8.7 61.7 ± 8.7 82.8 ± 8.7
0.5 80.0 ± 10.1 71.6 ± 8.5 77.5 ± 5.6 85.0 ± 6.7
1.0 76.0 ± 2.1 70.7 ± 6.0 75.5 ± 6.7 84.4 ± 6.5
5.0 80.1 ± 3.7 75.3 ± 10.0 85.5 ± 7.3 96.0 ± 1.6
10.0 70.5 ± 3.4 70.5 ± 7.8 85.5 ± 2.5 91.6 ± 4.2
20.0 54.1 ±8.1 74.1 ±9.0 77.1 ±9.5 87.8±5.8
Fresh whole blood was incubated with 99mTc-radiopharmaceuticals (99mTc-PHY, 99mTc-GHA,
99mTc-DMSA and 99mTc-DTPA) for 60 min at room temperature. After these incubations, the
blood preparations were centrifuged and plasma (P) and blood cells (BC) were isolated. Aliquots of
BC wereprecipitated with solutions oftrichloroacetic acid at various concentrations (20.0, 10.0, 5.0,
1.0, 0.5, 0.1 percent) and soluble (SF) and insoluble (IF) fractions from plasma were separated. The
samples were counted in awell counter withNaI(Tl) crystal and the percentage ofradioactivity (per-
cent rad) in IF-BC was determined dividing the counts in IF-BC by the sum ofthe counts in IF-BC
plus SF-BC. The values found were multiplied by 100. The values are averages ± standard devia-
tions of 8 experiments.Freitas et al.: 99mTc-radiopharmaceuticals bindings on bloodelements
the literature data. The 99mTc-PHY radioactivity is lower and the other radiopharmaceu-
ticals are higher in the plasma [1-2]. However, there are conflicting results described in
the literature about the binding of the radiopharmaceuticals to the blood elements [4-8].
We agree with De Ligny et al. [6] that the value found for the protein binding of99mTc-
radiopharmaceuticals appears to be dependent on the method used and on the experimen-
tal conditions. Nevertheless, our results indicate that other factors should be considered to
better evaluate the binding ofthe radiopharmaceuticals to blood elements. The radiophar-
maceutical uptake in organs may depend on its biochemical characteristics besides the
binding to blood elements. De Lingny et al. [6] have reported that protein binding to
99mTc-MDP does not occur, but Vanlic-Razumenic et al. [8] disagreed with this conclu-
sion and suggested that dissociation of the 99mTc-MDP-protein complex was a conse-
quence of excess dilution in their experiments.
Concerning 99mTc-PHY, Vanlic-Razumenic et al. [8] reported, using 10 percent
TCA, a percent rad in the IF-P of35.1. In our study, we found 38.1, however, ifwe choose
another TCA concentration, this value can vary between 36.4 and 65.0 percent.
Although the comparison ofour 99mTc-DMSA results (ifwe consider the TCA con-
centrations between 0.1 and 10.0 percent) are in agreement with the reported one [5, 8],
they are more similar to Gano et al. [5].
Savelkouk et al. [7] have shown that precipitation with TCA sometimes yields high
values, presumably by decomposition of the 99mTc-diphosphonate complexes in the
strongly acid solution and subsequent binding of the 99mTc to the denatured proteins.
Decomposition can also occur in gel chromatography and dialysis.
The general comparison with other results shows that for the fixation of the 99mTc-
radiopharmaceuticals to IF-BC there is a dependence on the TCA concentration: 99mTc-
PHY (0.1 to 5.0), 99mTc-DTPA (0.1 to 20.0), 99mTc-GHA (0.5 to 20.0) and 99mTc-
DMSA (5.0 to 10.0). If we compare the radiopharmaceuticals, they can present the same
capability to bind to the blood cells with 1.0 percent TCA, but ifwe employ 10.0 percent
TCA, 99mTc-DMSA=99mTc-GHA>99mTc-DTPA=99mTc-PHY.
Possibly this fact can be explained by (i) different affinity of the radiopharmaceuti-
cals to specific proteins on plasma and blood cells, (ii) different binding sites, (iii) pres-
ence of different stannous chloride concentrations [4, 10] and/or (iv) different formula-
tions of the kits [11].
We can speculate that the binding ofthe radiopharmaceuticals to blood elements and
the precipitation effect may depend on the characteristics of each radiopharmaceutical.
We suggest that the direct comparison among the various radiopharmaceuticals and the
differences in their capability to bind to protein complexes in the blood should be care-
fully carried out. The comparison of the binding of 99mTc-radiopharmaceuticals using
only one TCA concentration should be avoided. Thus, depending on the specific charac-
teristic ofeach radiopharmaceutical, it is possible that the TCA could (i) precipitate more
completely the proteins (to which the radiopharmaceutical is bound), (ii) affect the affin-
ity of the radiopharmaceutical for plasma and blood cell proteins, or (iii) dissociate the
99mTc from the radiopharmaceutical.
The correct determination ofthe binding ofradioactivity on blood elements is worth-
while (i) to understand how a drug is capable of modifying the biodistribution of radio-
pharmaceuticals, (ii) to evaluate the specific characteristics of the binding of each radio-
pharmaceutical to their targets in the blood, (iii) to avoid misdiagnosis, (iv) to avoid the
repetition of examinations, (v) to avoid poor organ visualization and (vi) to reduce the
radiation dose to the patients [1].
In conclusion, the complexity of radiopharmaceutical-protein binding may be
explained by the variety of proteins present in P and BC as well as the mechanisms
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involved in the labeling uptake and the type of each radiopharmaceutical. The study of
other radiopharmaceutials is now in progress
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